co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
ICICI Direct is bullish on Ajanta Pharmaceuticals recommended buy rating on the stock with a target price of Rs 1385 in its research report dated February 02, 2023.
ICICI Direct is bullish on Ajanta Pharmaceuticals recommended buy rating on the stock with a target price of Rs 1505 in its research report dated November 04, 2022.
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1495 in its research report dated July 29, 2022.
ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1305 in its research report dated June 22, 2022.
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1955 in its research report dated May 11, 2022.
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2605 in its research report dated February 02, 2021.
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2250 in its research report dated May 01, 2021.
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1960 in its research report dated November 04, 2020.
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1810 in its research report dated July 31, 2020.
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated May 22, 2020.
ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1010 in its research report dated August August 01, 2019.
The company, a major player in anti-malarial drugs in Africa, saw its business decline by 49 percent in FY19 compared to the previous year due to softening of tender business.
ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1060 in its research report dated May 02, 2019.
ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1100 in its research report dated February 01, 2019.
ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1190 in its research report dated May 03, 2018.
Dabur India is in talks to buy the 30-Plus multi-vitamin supplement brand from Ajanta Pharmaceuticals for less than 500 million rupees, the Economic Times reported on Monday.
